tbuckley/cabot-search huggingface dataset:
Effect of an Arsenic Mitigation Program on Arsenic Exposure in American Indian Communities: A Cluster Randomized Controlled Trial of the Community-Led Strong Heart Water Study Program
Authors: Christine Marie George, Tracy Zacher, Kelly Endres, Francine Richards, Lisa Bear Robe, David Harvey, Lyle G. Best, Reno Red Cloud, Annabelle Black Bear, Leslie Skinner, Christa Cuny, Ana Rule, Kellogg J. Schwab, Joel Gittelsohn, Ronald Alexander Glabonjat, Kathrin Schilling, Marcia O’Leary, Elizabeth D. Thomas, Jason Umans, Jianhui Zhu, Lawrence H. Moulton, Ana Navas-Acien
Journal: Environmental Health Perspectives (2024)

Chronic arsenic exposure has been associated with an increased risk of cardiovascular disease; diabetes; cancers of the lung, pancreas and prostate; and all-cause mortality in American Indian communities in the Strong Heart Study.
Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Authors: Matheus Henrique Dias, Anoek Friskes, Siying Wang, Joao M. Fernandes Neto, Frank van Gemert, Soufiane Mourragui, Chrysa Papagianni, Hendrik J. Kuiken, Sara Mainardi, Daniel Alvarez-Villanueva, Cor Lieftink, Ben Morris, Anna Dekker, Emma van Dijk, Lieke H.S. Wilms, Marcelo S. da Silva, Robin A. Jansen, Antonio Mulero-Sánchez, Elke Malzer, August Vidal, Cristina Santos, Ramón Salazar, Rosangela A.M. Wailemann, Thompson E.P. Torres, Giulia De Conti, Jonne A. Raaijmakers, Petur Snaebjornsson, Shengxian Yuan, Wenxin Qin, John S. Kovach, Hugo A. Armelin, Hein te Riele, Alexander van Oudenaarden, Haojie Jin, Roderick L. Beijersbergen, Alberto Villanueva, Rene H. Medema, Rene Bernards
Journal: Cancer Discovery (2024)

Abstract Cancer homeostasis depends on a balance between activated oncogenic pathways driving tumorigenesis and engagement of stress response programs that counteract the inherent toxicity of such aberrant signaling. Although inhibition of oncogenic signaling pathways has been explored extensively, there is increasing evidence that overactivation of the same pathways can also disrupt cancer homeostasis and cause lethality. We show here that inhibition of protein phosphatase 2A (PP2A) hyperactivates multiple oncogenic pathways and engages stress responses in colon cancer cells. Genetic and compound screens identify combined inhibition of PP2A and WEE1 as synergistic in multiple cancer models by collapsing DNA replication and triggering premature mitosis followed by cell death. This combination also suppressed the growth of patient-derived tumors in vivo. Remarkably, acquired resistance to this drug combination suppressed the ability of colon cancer cells to form tumors in vivo. Our data suggest that paradoxical activation of oncogenic signaling can result in tumor-suppressive resistance. Significance: A therapy consisting of deliberate hyperactivation of oncogenic signaling combined with perturbation of the stress responses that result from this is very effective in animal models of colon cancer. Resistance to this therapy is associated with loss of oncogenic signaling and reduced oncogenic capacity, indicative of tumor-suppressive drug resistance.
Non-invasive measurements of blood glucose levels by time-gating mid-infrared optoacoustic signals
Authors: Nasire Uluç, Sarah Glasl, Francesca Gasparin, Tao Yuan, Hailong He, Dominik Jüstel, Miguel A. Pleitez, Vasilis Ntziachristos
Journal: Nature Metabolism (2024)

Non-invasive glucose monitoring (NIGM) represents an attractive alternative to finger pricking for blood glucose assessment and management of diabetes. Nevertheless, current NIGM techniques do not measure glucose concentrations in blood but rely on indirect bulk measurement of glucose in interstitial fluid, where glucose is diluted and glucose dynamics are different from those in the blood, which impairs NIGM accuracy. Here we introduce a new biosensor, termed depth-gated mid-infrared optoacoustic sensor (DIROS), which allows, for the first time, non-invasive glucose detection in blood-rich volumes in the skin. DIROS minimizes interference caused by the stratum corneum and other superficial skin layers by time-gating mid-infrared optoacoustic signals to enable depth-selective localization of glucose readings in skin. In measurements on the ears of (female) mice, DIROS displays improved accuracy over bulk-tissue glucose measurements. Our work demonstrates how signal localization can improve NIGM accuracy and positions DIROS as a holistic approach, with high translational potential, that addresses a key limitation of current NIGM methods.
Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients
Authors: Shai Shimony, Jacqueline S. Garcia, Julia Keating, Evan C. Chen, Marlise R. Luskin, Maximilian Stahl, Donna S. Neuberg, Daniel J. DeAngelo, Richard M. Stone, R. Coleman Lindsley
Journal: Leukemia (2024)

Abstract The clinical impact of molecular ontogeny in acute myeloid leukemia (AML) was defined in patients treated with intensive chemotherapy. In a cohort of 314 newly diagnosed AML patients, we evaluated whether molecular ontogeny subgroups have differential benefit of venetoclax (VEN) added to hypomethylating agents (HMA). In secondary ontogeny ( n = 115), median overall survival (OS)(14.1 vs . 6.9 months, P = 0.0054), composite complete remission (cCR 61% vs . 18%, P &lt; 0.001) and allogeneic hematopoietic stem cell transplant (alloHCT) (24% vs . 6%, P = 0.02) rates were better in patients treated with HMA + VEN vs . HMA. In contrast, in TP53 AML( n = 111) median OS (5.7 vs . 6.1, P = 0.93), cCR (33% vs. 37%, P = 0.82) and alloHCT rates (15% vs . 8%, P = 0.38) did not differ between HMA + VEN vs. HMA. The benefit of VEN addition in the secondary group was preserved after adjustment for significant clinicopathologic variables (HR 0.59 [95% CI 0.38–0.94], P = 0.025). The OS benefit of HMA + VEN in secondary ontogeny was similar in those with vs . without splicing mutations ( P = 0.92). Secondary ontogeny AML highlights a group of patients whose disease is selectively responsive to VEN added to HMA and that the addition of VEN has no clinical benefit in TP53 -mutated AML.
Lymph Node Targeting Mediated by Albumin Hitchhiking of Synthetic Tn Glycolipid Leads to Robust In Vivo Antibody Production
Authors: Keerthana Thekke Veettil, Narayanaswamy Jayaraman
Journal: Advanced Healthcare Materials (2024)

Abstract Tn antigen is a tumor‐associated carbohydrate antigen, which is present prominently on the tumor cell surfaces and attracts an interest in vaccine development. This work demonstrates that a synthetic Tn antigen carrying glycoconjugate forms a complex with circulating albumin, delivers the antigen to lymph nodes (LNs), and leads to the efficient production of antibodies against the antigen. Synthetic Tn antigen glycoconjugate, possessing DSPE‐PEG2000 linker and lipophilic moieties, undergoes micellization in PBS buffer. In the presence of bovine serum albumin (BSA), demicellization of the glycolipid occurs, with a rate constant of 0.18 min −1 . In vitro studies show that the glycoconjugate binds preferentially to BSA in the presence of cells. Immunological assessments in mice models reveal the albumin‐enabled delivery of the Tn glycoconjugate to antigen‐presenting cells in the LNs, specifically leading to a robust humoral immune response. ELISA titers show superior binding, with a saturation dilution of 1:51 200 for Tn glycoconjugate, in comparison to that mediated by the Tn‐BSA covalent conjugate with a saturation dilution of 1:6400. Immunohistochemical staining shows delivery of Tn glycoconjugate at the LNs, specifically at the subcapsular sinus and interfollicular areas. The work highlights the potential of albumin‐mediated target delivery strategy for cancer immunotherapies.
Xenografted human microglia display diverse transcriptomic states in response to Alzheimer’s disease-related amyloid-β pathology
Authors: Renzo Mancuso, Nicola Fattorelli, Anna Martinez-Muriana, Emma Davis, Leen Wolfs, Johanna Van Den Daele, Ivana Geric, Jessie Premereur, Paula Polanco, Baukje Bijnens, Pranav Preman, Lutgarde Serneels, Suresh Poovathingal, Sriram Balusu, Catherine Verfaillie, Mark Fiers, Bart De Strooper
Journal: Nature Neuroscience (2024)

Abstract Microglia are central players in Alzheimer’s disease pathology but analyzing microglial states in human brain samples is challenging due to genetic diversity, postmortem delay and admixture of pathologies. To circumvent these issues, here we generated 138,577 single-cell expression profiles of human stem cell-derived microglia xenotransplanted in the brain of the App NL-G-F model of amyloid pathology and wild-type controls. Xenografted human microglia adopt a disease-associated profile similar to that seen in mouse microglia, but display a more pronounced human leukocyte antigen or HLA state, likely related to antigen presentation in response to amyloid plaques. The human microglial response also involves a pro-inflammatory cytokine/chemokine cytokine response microglia or CRM response to oligomeric Aβ oligomers. Genetic deletion of TREM2 or APOE as well as APOE polymorphisms and TREM2 R47H expression in the transplanted microglia modulate these responses differentially. The expression of other Alzheimer’s disease risk genes is differentially regulated across the distinct cell states elicited in response to amyloid pathology. Thus, we have identified multiple transcriptomic cell states adopted by human microglia in a multipronged response to Alzheimer’s disease-related pathology, which should be taken into account in translational studies.
Long-term in vivo three-photon imaging reveals region-specific differences in healthy and regenerative oligodendrogenesis
Authors: Michael A. Thornton, Gregory L. Futia, Michael E. Stockton, Samuel A. Budoff, Alexandra N. Ramirez, Baris Ozbay, Omer Tzang, Karl Kilborn, Alon Poleg-Polsky, Diego Restrepo, Emily A. Gibson, Ethan G. Hughes
Journal: Nature Neuroscience (2024)
TREM1 disrupts myeloid bioenergetics and cognitive function in aging and Alzheimer disease mouse models
Authors: Edward N. Wilson, Congcong Wang, Michelle S. Swarovski, Kristy A. Zera, Hannah E. Ennerfelt, Qian Wang, Aisling Chaney, Esha Gauba, Javier A. Ramos Benitez, Yann Le Guen, Paras S. Minhas, Maharshi Panchal, Yuting J. Tan, Eran Blacher, Chinyere A. Iweka, Haley Cropper, Poorva Jain, Qingkun Liu, Swapnil S. Mehta, Abigail J. Zuckerman, Matthew Xin, Jacob Umans, Jolie Huang, Aarooran S. Durairaj, Geidy E. Serrano, Thomas G. Beach, Michael D. Greicius, Michelle L. James, Marion S. Buckwalter, Melanie R. McReynolds, Joshua D. Rabinowitz, Katrin I. Andreasson
Journal: Nature Neuroscience (2024)
A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results
Authors: Amy R. Rappaport, Chrisann Kyi, Monica Lane, Meghan G. Hart, Melissa L. Johnson, Brian S. Henick, Chih-Yi Liao, Amit Mahipal, Ardaman Shergill, Alexander I. Spira, Jonathan W. Goldman, Ciaran D. Scallan, Desiree Schenk, Christine D. Palmer, Matthew J. Davis, Sonia Kounlavouth, Lindsey Kemp, Aaron Yang, Yaojun John Li, Molly Likes, Annie Shen, Gregory R. Boucher, Milana Egorova, Robert L. Veres, J. Aaron Espinosa, Jason R. Jaroslavsky, Lauren D. Kraemer Tardif, Lindsey Acrebuche, Christopher Puccia, Leiliane Sousa, Rita Zhou, Kyounghwa Bae, J. Randolph Hecht, David P. Carbone, Benny Johnson, Andrew Allen, Andrew R. Ferguson, Karin Jooss
Journal: Nature Medicine (2024)
Cardiac GR Mediates the Diurnal Rhythm in Ventricular Arrhythmia Susceptibility
Authors: Roman Tikhomirov, Robert H. Oakley, Cali Anderson, Yirong Xiang, Sami Al-Othman, Matthew Smith, Sana Yaar, Eleonora Torre, Jianying Li, Leslie R. Wilson, David R. Goulding, Ian Donaldson, Erika Harno, Luca Soattin, Holly A. Shiels, Gwilym M. Morris, Henggui Zhang, Mark R. Boyett, John A. Cidlowski, Pietro Mesirca, Matteo E. Mangoni, Alicia D’Souza
Journal: Circulation Research (2024)

Ventricular arrhythmias (VAs) demonstrate a prominent day-night rhythm, commonly presenting in the morning. Transcriptional rhythms in cardiac ion channels accompany this phenomenon, but their role in the morning vulnerability to VAs and the underlying mechanisms are not understood. We investigated the recruitment of transcription factors that underpins transcriptional rhythms in ion channels and assessed whether this mechanism was pertinent to the heart's intrinsic diurnal susceptibility to VA.
Interleukin 31 transcription in a canine model of acute atopic dermatitis does not correlate with T‐cell infiltration
Authors: Nicky Craig, Kim Ahrens, Rachel Wilkes, Tanja Opriessnig, Deborah V. Hoyle, Barry Bradford, Scott Maxwell, Jorge del Pozo, Maciej Parys, Takanori Kitamura, Rosanna Marsella
Journal: Allergy (2024)

The data that support the findings of this study are available from the corresponding author upon reasonable request. Data S1. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Mast cell activation identified through urine mediators
Authors: Matthew P. Giannetti, Grace Godwin, Julia Middlesworth, Andrew Espeland, Jennifer Nicoloro‐SantaBarbara, Mariana Castells
Journal: Allergy (2024)

The data that support the findings of this study are available from the corresponding author upon reasonable request. Figure S1. Appendix S1. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Comprehensive transition of care for polycystic ovary syndrome from adolescence to adulthood
Authors: Stacey L Simon, Phoutdavone Phimphasone-Brady, Kathryn M McKenney, Lauren D Gulley, Andrea E Bonny, Jaime M Moore, Carla Torres-Zegarra, Melanie G Cree
Journal: The Lancet Child & Adolescent Health (2024)
Corrigendum to “131I-αPD-L1 immobilized by bacterial cellulose for enhanced radio-immunotherapy of cancer” [Journal of Controlled Release 346 (2022) 240–249]
Authors: Zhongyuan Qi, Pei Pei, Yanxiang Zhang, Hua Chen, Sai Yang, Teng Liu, Yujuan Zhang, Kai Yang
Journal: Journal of Controlled Release (2024)
Exosomal long non-coding RNA TRPM2-AS promotes angiogenesis in gallbladder cancer through interacting with PABPC1 to activate NOTCH1 signaling pathway
Authors: Zhiqiang He, Yuhan Zhong, Parbatraj Regmi, Tianrun Lv, Wenjie Ma, Junke Wang, Fei Liu, Siqi Yang, Yanjie Zhong, Rongxing Zhou, Yanwen Jin, Nansheng Cheng, Yujun Shi, Haijie Hu, Fuyu Li
Journal: Molecular Cancer (2024)

Abnormal angiogenesis is crucial for gallbladder cancer (GBC) tumor growth and invasion, highlighting the importance of elucidating the mechanisms underlying this process. LncRNA (long non-coding RNA) is widely involved in the malignancy of GBC. However, conclusive evidence confirming the correlation between lncRNAs and angiogenesis in GBC is lacking.
An Electroconductive and Antibacterial Adhesive Nanocomposite Hydrogel for High‐Performance Skin Wound Healing (Adv. Healthcare Mater. 8/2024)
Authors: Wen Zheng, Wenyue Yang, Wenlong Wei, Ziru Liu, Pier‐Luc Tremblay, Tian Zhang
Journal: Advanced Healthcare Materials (2024)
Strengthening the Combinational Immunotherapy from Modulating the Tumor Inflammatory Environment via Hypoxia‐Responsive Nanogels (Adv. Healthcare Mater. 8/2024)
Authors: Wenhe Luo, Yanqiao Zeng, Qingle Song, Yu Wang, Feng Yuan, Qi Li, Yingnan Liu, Su Li, Nahar Jannatun, Guofang Zhang, Yang Li
Journal: Advanced Healthcare Materials (2024)
Copper Nanodots‐Based Hybrid Hydrogels with Multiple Enzyme Activities for Acute and Infected Wound Repair (Adv. Healthcare Mater. 8/2024)
Authors: Yuyu Cui, Wei Zhang, Jie Shan, Jia He, Qiang Niu, Can Zhu, Wenqi Wang, Xu‐Lin Chen, Xianwen Wang
Journal: Advanced Healthcare Materials (2024)
Comparative Analysis of Various Spider Silks in Regard to Nerve Regeneration: Material Properties and Schwann Cell Response (Adv. Healthcare Mater. 8/2024)
Authors: Sarah Stadlmayr, Karolina Peter, Flavia Millesi, Anda Rad, Sonja Wolf, Sascha Mero, Martin Zehl, Axel Mentler, Claudia Gusenbauer, Johannes Konnerth, Hannes C. Schniepp, Helga Lichtenegger, Aida Naghilou, Christine Radtke
Journal: Advanced Healthcare Materials (2024)

RegeneRative embRaceIn article 2302968, Sarah Stadlmayr, Aida Naghilou, and co-workers investigate the potential of spider silks as new biomaterials to enhance directional support in nerve guidance conduits, providing a detailed look at Schwann cell -spider silk interactions.The image is a 3D rendering of a confocal microscopy image created by Maximilian Haertinger showing a Schwann cell on the silk of a Golden Orb-Weaver spider.
Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes
Authors: Laurent Castera, Philippe Garteiser, Cédric Laouenan, Tiphaine Vidal-Trécan, Anaïs Vallet-Pichard, Pauline Manchon, Valérie Paradis, Sébastien Czernichow, Dominique Roulot, Etienne Larger, Stanislas Pol, Pierre Bedossa, Jean-Michel Correas, Dominique Valla, Jean-François Gautier, Bernard E. Van Beers, Djamila Bellili, Ouarda Bessadi, Charlene Da Silveira, Fatima Zohra Djelouat, Benoit Girard, Vanessa Legrand, Nathalie Neveux, Meriam Meziani, Ludovic Roy, Dahia Sekour, Manon Sens, Miassa Slimani, Ouassila Zatout, Delphine Bachelet, Krishna Bhavsar, Basma Basli-Baillet Jimmy Mullaert, Estelle Marcault, Nassima Si-Mohammed, Emmanuel Cosson, None Miguel Albuquerque, Sabrina Doblas, Adel Hammoutene, Estefania Gonzalez Montpetit, Gwenaël Pagé, None Béatrice Parfait, Catherine Postic, Agnès Lehuen, Amine Toubal, Camille Rousseau, Blandine Fruchet, Pauline Soulard, Zouriatou Gouda, Michel Vidaud, Franck Letourneur, Gilles Renault, Raphaël Scharfmann, Amel Ait-Boudaoud, Charles Barsamian, Claire Carette, Claire Rives-Lange, Rachel Baida, Olivier Couture, Sofiane Decombas, Thomas Deffieux, Thu-mai Nguyen, Mickael Tanter, Tania Baltauss, Edwige-Ludiwyne Balzac, Pierre Barbier Saint Hilaire, Philippe Delerive, Valérie Duvivier, Arnaud Fillon, Julia Geronimi, Jessica Laplume, Erwan Werner, Laura Xuereb, Robin Liechti, Olivier Martin, Florence Mehl, Manuela Pruess, Jean-Marie Castille, Fabienne Drane, Olivier Deckmyn, Florence Castelli, Benoit Colsch Emmanuel Cousin, François Fenaille, Laure Guilbaud, Allyre Lohier, Francois Chambellin, Lyddie Laaland, Catherine Clusel, Marie Hauduroy, Pierre Pautre
Journal: Journal of Hepatology (2024)
Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial
Authors: Renske M T ten Ham, Maartje W Rohaan, Inge Jedema, Rob Kessels, Wim Stegeman, Walter Scheepmaker, Bastiaan Nuijen, Cynthia Nijenhuis, Melanie Lindenberg, Troels Holz Borch, Tine Monberg, Marco Donia, Inge Marie Svane, Wim van Harten, John Haanen, Valesca P Retel
Journal: Journal for ImmunoTherapy of Cancer (2024)

In a multicenter, open-label randomized phase 3 clinical trial conducted in the Netherlands and Denmark, treatment with ex vivo-expanded tumor-infiltrating lymphocytes (TIL-NKI/CCIT) from autologous melanoma tumor compared with ipilimumab improved progression-free survival in patients with unresectable stage IIIC-IV melanoma after failure of first-line or second-line treatment. Based on this trial, we conducted a cost-utility analysis. A Markov decision model was constructed to estimate expected costs (expressed in 2021€) and outcomes (quality-adjusted life years (QALYs)) of TIL-NKI/CCIT versus ipilimumab in the Netherlands. The Danish setting was assessed in a scenario analysis. A modified societal perspective was applied over a lifetime horizon. TIL-NKI/CCIT production costs were estimated via activity-based costing. Through sensitivity analyses, uncertainties and their impact on the incremental cost-effectiveness ratio (ICER) were assessed. Mean total undiscounted lifetime benefits were 4.47 life years (LYs) and 3.52 QALYs for TIL-NKI/CCIT and 3.33 LYs and 2.46 QALYs for ipilimumab. Total lifetime undiscounted costs in the Netherlands were €347,168 for TIL-NKI/CCIT (including €67,547 for production costs) compared with €433,634 for ipilimumab. Undiscounted lifetime cost in the Danish scenario were €337,309 and €436,135, respectively. This resulted in a dominant situation for TIL-NKI/CCIT compared with ipilimumab in both countries, meaning incremental QALYs were gained at lower costs. Survival probabilities, and utility in progressive disease affected the ICER most. Based on the data of a randomized phase 3 trial, treatment with TIL-NKI/CCIT in patients with unresectable stage IIIC-IV melanoma is cost-effective and cost-saving, both in the current Dutch and Danish setting. These findings led to inclusion of TIL-NKI/CCIT as insured care and treatment guidelines. Publicly funded development of the TIL-NKI/CCIT cell therapy shows realistic promise to further explore development of effective personalized treatment while warranting economic sustainability of healthcare systems.
Poor clinical outcomes and immunoevasive contexture in CD161<sup>+</sup>CD8<sup>+</sup>T cells barren human pancreatic cancer
Authors: Qiangda Chen, Hanlin Yin, Zhenlai Jiang, Taochen He, Yuqi Xie, Weilin Mao, Jiande Han, Siyao Liu, Wenhui Lou, Wenchuan Wu, Joseph R Habib, Jun Yu, Liang Liu, Ning Pu
Journal: Journal for ImmunoTherapy of Cancer (2024)

The role of CD161 expression on CD8+ T cells in tumor immunology has been explored in a few studies, and the clinical significance of CD161+CD8+ T cells in pancreatic ductal adenocarcinoma (PDAC) remains unclear. This study seeks to clarify the prognostic value and molecular characteristics linked to CD161+CD8+ T cell infiltration in PDAC. This study included 186 patients with confirmed PDAC histology after radical resection. CD161+CD8+ T cell infiltration was assessed using immunofluorescence staining on tumor microarrays. Flow cytometry and single-cell RNA sequencing were used to evaluate their functional status. We observed significant associations between tumor-infiltrating CD161+CD8+ T cells and clinicopathological factors, such as tumor differentiation, perineural invasion, and serum CA19-9 levels. Patients with higher tumor-infiltrating CD161+CD8+ T cell levels had longer overall survival (OS) and recurrence-free survival (RFS) than those with lower levels. Multivariable analysis confirmed tumor-infiltrating CD161+CD8+ T cell as an independent prognostic indicator for both OS and RFS. Notably, a combination of tumor-infiltrating CD161+CD8+ T cell and CA19-9 levels showed a superior power for survival prediction, and patients with low tumor-infiltrating CD161+CD8+ T cell and high CA19-9 levels had the worst survival. Furthermore, lower tumor-infiltrating CD161+CD8+ T cells were associated with a better response to adjuvant chemotherapy. Finally, we identified tumor-infiltrating CD161+CD8+ T cells as a unique subtype of responsive CD8+ T cells characterized by increased levels of cytotoxic cytokines and immune checkpoint molecules. CD161+CD8+ T cells exhibit elevated levels of both cytotoxic and immune-checkpoint molecules, indicating as a potential and attractive target for immunotherapy. The tumor-infiltrating CD161+CD8+ T cell is a valuable and promising predictor for survival and therapeutic response to adjuvant chemotherapy in PDAC. Further research is warranted to validate its role in the risk stratification and optimization of therapeutic strategies.
Clinical Connections
Journal: Arthritis & Rheumatology (2024)

Arthritis is a common immune-related adverse event associated with the use of checkpoint inhibitor therapies, which suggests the regulatory role of PD-1/PD-L1 pathway in the joint.• more severe arthritis, showing that PD-L1+ macrophages • PD-L1+ macrophages in the joints upregulate antimolecules during arthritis in both mice and humans.